English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Acute renal transplant rejection isone of the most important complications of thismedical procedure. This study compares the first year rate of rejection in patients that receiveddaclizumab or basiliximab as initial immunosuppression induction drug. Methods It s an observational, retrospectivecohort study and includes patients between January 2000 and December 2008. The source ofpatients was the Nephrology Service of Calderon Guardia Hospital. The target population was allthe patients with renal transplant whom receivedbasiliximab or daclizumab as initial immunosuppression induction drug. Results Acute renal transplant rejection wasmore often seen in the group of patients thatreceived basiliximab, compared with the daclizumab group. Discussion The acute renal rejection rate in thefirst year post surgery in Calderon Guardia Hospital, showed statistically significant differencesbetween the daclizumab group and the basiliximab group. In the basiliximab group there wheremore patients with acute rejection.

revista clínica de la escuela de medicina ucr-hsjd

COMPARACIÓN DEL RECHAZO AGUDO DURANTE EL PRIMER AÑO DEL INJERTO EN PACIENTES TRASPLANTADOS RENALES QUE RECIBIERON BASILIXIMAB O DACLIZUMAB. HOSPITAL CALDERÓN GUARDIA. PERÍODO 2000-2008